Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164018 | 1.00 | USP2 (0.43) | USP2MAPK1PDE2AALDH1A1ADORA3 | |
| SCHEMBL20164016 | 1.00 | USP2 (0.43) | USP2MAPK1PDE2AALDH1A1ADORA3 | |
| SCHEMBL21652122 | 0.86 | USP2 (0.41) | USP2MAPK1PDE2AALDH1A1ADORA3 | |
| SCHEMBL20175968 | 0.80 | PDE2A (0.37) | USP2MAPK1PDE2AALDH1A1ADORA3 | |
| SCHEMBL20175962 | 0.80 | PDE2A (0.37) | USP2MAPK1PDE2AALDH1A1ADORA3 | |
| SCHEMBL18362196 | 0.80 | PDE2A (0.38) | PDE2AKMT2AMEN1 | |
| SCHEMBL20164023 | 0.77 | PDE2A (0.49) | PDE2AKMT2AMEN1 | |
| SCHEMBL20164024 | 0.77 | PDE2A (0.49) | PDE2AKMT2AMEN1 | |
| SCHEMBL20164051 | 0.77 | PDE2A (0.49) | PDE2AKMT2AMEN1 | |
| SCHEMBL16968244 | 0.66 | ALDH1A1 (0.44) | USP2MAPK1ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3319966-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-01-29 | — | — | EP | disclosed |
| US-10287293-B2 | Bicyclic heterocyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287293-B2 | Bicyclic heterocyclic compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | USP2 1400/4885MAPK1 1288/4885PDE2A 1/4885 |
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | USP2 1400/4885MAPK1 1288/4885PDE2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.